Your Messages Inbox
Your Article Summary
See Latest ArticlesFDA approves Micardis as the first treatment in its class to reduce the risk of heart attack, stroke, or death from cardiovascular causes in patients at high cardiovascular risk who are unable to take ACE inhibitors
Boehringer Ingelheim, 10/20/09
Boehringer Ingelheim announced that the US Food and Drug Administration has approved a new indication for Micardis for the reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. Micardis is the first treatment in its class to be approved for this indication.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
FDA Advisory Committee Supports Use of Aztreonam for Inhalation Solution for Patients with Cystic Fibrosis
Gilead, 12/14/09
Greater chances of cure for patients with HER2-positive early breast cancer when treated with one year of Herceptin
Roche, 12/14/09
Article Search
Sponsor